There are 2867 resources available
463P - Efficacy and safety of larotrectinib in a pooled analysis of patients (Pts) with tropomyosin receptor kinase (TRK) fusion cancer with an extended follow-up
Presenter: Raymond Sean McDermott
Session: Poster session 13
464P - Intra-patient (Pt) comparison from larotrectinib (Laro) clinical trials in tropomyosin receptor kinase (TRK) fusion cancer: An expanded dataset
Presenter: Antoine Italiano
Session: Poster session 13
465P - Larotracking: Real-life study of locally advanced/metastatic solid tumor treated with larotrectinib in French expanded access program
Presenter: Armelle Dufresne
Session: Poster session 13
466P - Efficacy of BRAF inhibitor FORE8394 in BRAF V600+ patients
Presenter: Eric Sherman
Session: Poster session 13
467P - Dose escalation of TAS-117 in patients with advanced solid tumors
Presenter: Jordi Rodon
Session: Poster session 13
468P - Clinical benefit of alpelisib in pediatric patients with PIK3CA-related overgrowth spectrum (PROS): An EPIK-P1 analysis
Presenter: Guillaume Canaud
Session: Poster session 13
469P - A phase I study of palbociclib in combination with cisplatin or carboplatin in advanced solid malignancies
Presenter: Olatunji Alese
Session: Poster session 13
470P - Preclinical assessment of the pharmacokinetics, disposition, and duration of action of the dual alphav-integrin and neuropilin-1 targeting peptide CEND-1
Presenter: Harri Järveläinen
Session: Poster session 13
472P - Prognostic markers in patients (pts) with solid tumors submitted to bispecific T-cell engagers in phase I (phI) clinical trials
Presenter: Mateus Cunha
Session: Poster session 13
473P - Phase I study of GFH018, a small molecular TGF-βRI inhibitor, in patients (pts) with advanced solid tumors
Presenter: Ye Guo
Session: Poster session 13